Overview

Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2015-01-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of the combination of two drugs called RAD001 and AMG479. This study will see what effects (good and bad) RAD001 and AMG479 have on cancer. This study will also find the highest doses of RAD001 and AMG479 that can be given without causing severe side effects.
Phase:
Phase 1
Details
Lead Sponsor:
Shadia Jalal
Collaborators:
Amgen
Novartis
Treatments:
Antibodies, Monoclonal
Everolimus
Sirolimus